A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
Latest Information Update: 17 Apr 2023
At a glance
- Drugs Denosumab (Primary) ; Enzalutamide (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms DICE
Most Recent Events
- 03 Dec 2019 Status changed from recruiting to suspended.
- 14 Mar 2019 New trial record